Hims & Hers rises on Trump push for direct-to-consumer purchasing program

** Shares of telehealth co Hims & Hers Health HIMS.N rise 8.1% to $56.17

** U.S. President Donald Trump's executive order (EO) directs government to consider facilitating direct-to-consumer purchasing programs that will sell drugs at prices other countries pay

** Trump has signed wide-reaching EO directing drugmakers to lower prices of medicines to align with what other countries pay, which analysts and legal experts say will be difficult to implement

** " If the executive order pushes to broader adoption of direct-to-consumer pricing, that would be a positive for HIMS given its infrastructure," Leerink Partners says

** "For one, we still need to see precisely how this will be enacted. An EO on its own is not necessarily law (many EOs have never led to any substantial changes), so the execution of the EO will be important to the eventual impact to the group," brokerage adds

** Including session's moves, stock more than doubled YTD